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Oesophageal cancer is a highly malignant disease associated with a
dismal prognosis (Walsh et al, 1996; Bosset et al, 1997). The inci-
dence of oesophageal adenocarcinoma has risen 6- to 8-fold in
Western Europe and in the US over the past 3 decades (Cohen and
Parkman, 1999). By contrast, the incidence of oesophageal squa-
maous carcinoma has remained static. It has been recognised that
Barrett’s oesophagus, a result of chronic gastro-oesophageal reflux,
is the key intermediary step in the development of oesophageal
adenocarcinoma. A recent report however, has suggested that
chronic symptomatic gastro-oesophageal reflux, even in the absence
of Barrett’s oesophagus, may be an independent risk factor for the
development of oesophageal adenocarcinoma (Lagergren et al,
1999). Therefore, identification of factors which modulate the risk
of development of oesophageal cancer in patients with reflux
oesophagitis or Barrett’s oesophagus, could prove of great value in
the future, in structuring screening programmes. 
To date, no susceptibility genes for oesophageal adenocarci-
noma or squamous cancer have been identified. The molecular
biology of oesophageal cancer is poorly defined (Montesano et al,
1996). Tumours are often described at an advanced stage, by
which time they have accumulated a diversity of mutations and
deletions. In contrast with other tumour types however, p53 muta-
tion appears to be an early event in oesophageal carcinogenesis
(Montesano et al, 1996; Barrett et al, 1999). A recent study has
indicated that the evolution of neoplastic cell lineages in Barrett’s
oesophagus and oesophageal adenocarcinoma is complex,
involving non-random loss of heterozygosity (LOH), duplications
and mutations which do not occur in a particular obligate order
(Barrett et al, 1999). 
Recently, p73, a novel structural and functional homologue of
p53 was identified (Kaghad et al, 1997). p73 maps to chromosome
1p36 (Kaghad et al, 1997), a region deleted in up to 40% of
oesophageal cancers (Barrett et al, 1996). p73 is a putative
imprinted tumour suppressor gene, which has been shown to be
imprinted in some, but not all human tissues investigated to date
(Kaghad et al, 1997; Mai et al, 1998a, 1998b; Nomoto et al, 1998;
Yokomizo et al, 1999). Loss of heterozygosity (LOH) at the p73
locus has been reported with varying frequency in different
tumours; 5.3% of prostatic cancers (Takahashi et al, 1998), 19% of
neuroblastomas (Ichimiya et al, 1999), 42% of lung cancers
(Nomoto et al, 1998) and 8% (Nimura et al, 1998) and 64% (Cai
et al, 2000) of oesophageal cancers have reported p73 LOH.
However, extensive mutational analysis of p73 in diverse tumours
has demonstrated that mutations in this gene are rare, being
reported in fewer than 2% of all cancers screened (Mai et al,
1998b; Takahashi et al, 1998; Yokomizo et al, 1999), suggesting
that this gene does not function as a traditional tumour-suppressor
gene. Two linked, single nucleotide polymorphisms, forming a
compound polymorphism at positions 4 (G→ A) and 14 (C→ T)
have been identified in the 5′ untranslated region (UTR), of exon 2
of the p73 gene (Kaghad et al, 1997), and have been designated the
AT and GC alleles respectively. This polymorphism lies just
upstream of the initiating AUG of exon 2, in a region which may
theoretically form a stem-loop structure. It has been suggested that
this could potentially affect gene expression, perhaps through
alteration of the efficiency of translation initiation (Kaghad et al,
1997). Recently, a p73-knockout mouse model has been devel-
oped; these mice manifested various neurohormonal deficits and
also inflammatory defects, in particular, the mice exhibited severe
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In this study, we sought to investigate whether the AT/GC poly-
morphism in the p73 gene may play a role in the pathogenesis of
oesophageal cancer. To this end, we analysed the p73 genotype of
84 oesophageal cancer cases and compared with that of 152
healthy normal population controls. Furthermore, we investigated
the frequency of p73 LOH in informative cases. 
MATERIALS AND METHODS 
Cases and controls 
152 healthy age- and sex-matched normal population controls
were chosen from a databank of controls stored at our institution.
This databank contains over 300 whole blood samples from both
healthy individuals working at the hospital, and healthy elderly
individuals in the community, with an age range from 21–86 years.
DNA was extracted from whole blood. Ethical approval was
obtained from our institution’s Ethics Committee. 
84 cases of oesophageal cancer, diagnosed between 1997 and
1999, and for whom tissue samples were readily available, were
identified from the hospital oesophageal cancer database (25 squa-
mous carcinomas and 59 adenocarcinomas) which contains over
400 cases of oesophageal carcinoma diagnosed since 1990 (Walsh
et al, 1996). Normal genomic DNA was extracted either from a
sample of normal frozen or paraffin-embedded tissue (57 cases),
or from a whole blood sample where available (27 cases). Tumour
DNA was extracted either from frozen or paraffin-embedded
tissue. All frozen tissue samples were snap frozen in liquid
nitrogen, and stored at –80˚C until analysed. Two oesophageal cell
lines were also examined, a squamous carcinoma (ECACC ref. #
OE21) and an adenocarcinoma cell line (ECACC ref. # OE 19). 
DNA isolation 
Tumour DNA was isolated from 50–100 mg of frozen tissue
sample using the Genosys RNA Isolator® kit, or from paraffin-
embedded specimens using a standard phenol/chloroform precipi-
tation protocol. DNA was isolated from whole blood samples
using Qiagen® blood mini-kits. 
Genotyping and examination of LOH at the p73 locus 
The polymorphic region of exon 2 of the p73 gene was amplified
from genomic DNA extracted from both normal and tumour
tissues, using previously described primers (Yokomizo et al,
1999). The PCR product was then digested with Sty I (New
England Biolabs). The presence of the AT polymorphism creates a
Sty I digestion site, yielding products of 157 bp and 72 bp; the GC
allele remains uncleaved by Sty I, yielding a 229 bp product. The
products were then resolved by electrophoresis on 2% agarose
(Figure 1). In all experiments, an AT/AT homozygote was
included, to act as a control for complete digestion of the PCR
products by the Sty I enzyme. 
Statistical analysis 
Patient and control populations were compared for differences in
genotype frequencies using a χ 2 test (SAS, statistical analysis soft-
ware). Divergences in allele distribution within populations, from
those predicted under Hardy–Weinberg equilibrium, were tested
for significance using GENEPOP software, version 3.1b
(Raymond and Rousset, 1995). 
RESULTS 
Genotypic analysis of cases and controls 
Genetic analysis of the patient and control populations demon-
strated that the AT/AT genotype was significantly less prevalent in
the cancer group compared to the normal population (1.2% v
9.9%, P < 0.02) (Table 1). Furthermore, as genotype frequencies
within a given population are inextricably linked, both populations
were concomitantly examined for differences between all geno-
type frequencies, giving a total χ 2 across groups of 6.527 (2
degrees of freedom, P = 0.038); the vast bulk of which was attrib-
utable to the difference between AT/AT homozygotes. The AT
homozygote was only detected in 1/25 squamous carcinomas and
0/59 adenocarcinomas (Table 1). The odds ratio (OR) for develop-
ment of oesophageal cancer in AT/AT homozygotes compared to
all other genotypes was 0.11 (95% CI = 0.02–0.6), corresponding
to a 9-fold reduced risk in these individuals. Despite the marked
differences in allele distribution, the overall AT allele frequency
was only slightly lower in the cancer (0.2559) compared to the
control (0.3125) population (P = n.s.); reduced numbers of
homozygotes are compensated by an excess of AT/GC heterozy-
gotes in the patient population (Table 1). 
Hardy–Weinberg equilibrium analysis of allele distribution
within our cancer and control populations was performed (Table
2). The allele distribution in the cancer population deviated signif-
icantly (P = 0.0099, GENEPOP (Raymond and Rousset, 1995)),
from that expected. In the cancer population the prevalence of
AT/AT (and also GC/GC) homozygotes was lower than expected,
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Table 1: Demographics and p73 genotype frequencies in the control and oesophageal cancer populations 
GENOTYPE (n %)
n Median age (y) Age range (y) AT/AT AT/GC GC/GC AT allele frequency P value 
Controls 152 58 43–86 15 (9.9)* 65 (42.8) 72 (47.3) 0.3125¶ *P < 0.02 
*OR 0.11 (0.02–0.6) 
Oesophageal Cancer Cases 84 73 53–77 1 (1.2)* 41 (48.8) 42 (50) 0.2559¶ P = ns 
Adenocarcinomas 59 72.5 48–72 0 (0) 29 (49.1) 30 (50.8) 0.2458 
Squamous carcinomas 25 74 53–77 1 (4) 12 (48) 12 (48) 0.2800 
*AT/ATs were significantly less frequent in the cancer population, with an odds ratio (OR) for development of oesophageal cancer in AT/ATs of 0.11 (95% CI
0.02–0.6). This was significant also when adenocarcinoma cases were analysed separately, but not when squamous cancers were analysed separately, due to
the small numbers in this group. ¶There was no significant difference in AT allele frequency between the cases and controls. whereas there was heterozygote excess (Table 2). In contrast, the
allele distribution in the control population was almost exactly as
predicted (Table 2). 
Loss of heterozygosity in informative cases 
Tumour tissue was available for 37/41 heterozygote cases. p73
LOH was demonstrated in 14/37 cases (37.8%). In all instances of
p73 LOH, we observed exclusive loss of the AT allele (Figure 1;
lanes 8 & 9 and lanes 12 & 13). We also studied two oesophageal
carcinoma cell lines, ECACC #OE21 (squamous carcinoma) and
ECACC #OE19 (adenocarcioma), both of which were GC
homo/hemi-zygotes. 
DISCUSSION 
We found a significant association between the p73 AT/GC poly-
morphism and the risk of developing oesophageal cancer. AT/AT
homozygotes in our study were significantly less prevalent in the
oesophageal cancer population, both in adenocarcinomas (0/59)
and squamous carcinomas (1/25), compared to the control popula-
tion, OR 0.11 (95% CI 0.02–0.6, P < 0.02). Adenocarcinomas and
squamous carcinomas were analysed together, because of the
smaller numbers in each separate group. AT/AT homozygotes
were significantly less frequent than expected in the cancer popu-
lation, given the frequency of the AT allele in this group (P =
0.0099). Deviations from Hardy–Weinberg equilibrium such as
those observed in this study, are strongly suggestive of an under-
lying selective process, which in this instance, appears to militate
against the development of oesophageal cancer in AT/AT homozy-
gotes. Population admixture may cause artefactual associations
between allelic variants and disease risk (Altshuler et al, 1998),
however, there is little or no population admixture in our study
population (Irish), and both our control and cancer groups were
derived from this homogenous population. 
In this study, LOH of the p73 locus was observed in 37.8% of
informative (AT/GC heterozygote) oesophageal cancer cases.
Importantly, there was exclusive loss of the AT allele in all
instances of LOH, again, suggesting a specific functional role for
the AT allele. A number of previous studies which have identified
LOH at the p73 locus in various human cancers, have not reported
exclusive deletion of the AT allele (Nomoto et al, 1998; Takahashi
et al, 1998; Ichimiya et al, 1999). However, in the landmark p73
study, which examined tumour cell lines from a variety of origins,
only 3/19 (16%) had the AT allele present at genomic level
(Kaghad et al, 1997), the remainder being GC homo/hemi-zygotes.
This suggests that loss of the p73 AT allele may also occur in
cancers of other tissue origins. Two previous studies have investi-
gated LOH at the p73 locus in oesophageal cancer patients of
Asian ethnic background, and have reported vastly differing
frequencies of LOH, ranging from 8% (2/25) (Nimura et al, 1998)
to 64% (9/14) (Cai et al, 2000). In the most recent report, which
found LOH in 64% of all informative cases, in 82% of instances,
there was loss of the AT allele (Cai et al, 2000), similar to that
observed in our current study. 
In contrast with other tumour types, p53 mutation is an early
event in oesophageal carcinogenesis (Montesano et al, 1996;
Barrett et al, 1999). P53 is a critical regulator of the cell cycle
(Levine, 1997) and p73 shares significant functional homology
with p53 (Kaghad et al, 1997; Zhu et al, 1998). Existing evidence
shows that p73 plays a role in the regulation of the cell cycle,
apoptosis and possibly control of differentiation (Jost et al, 1997;
Kaghad et al, 1997; DeLaurenzi et al, 1998; Zhu et al, 1998; Gong
et al, 1999), all of which are critical in the oncogenic process.
These existing data suggest that p73 activity may be capable of
compensating, to some extent, for the early loss of p53 function
(through mutation) observed in pre-cancerous oesophageal lesions
(Barrett et al, 1999). Indeed, supporting this hypothesis, is the
observation that increased expression of p73 was found in
oesophageal squamous cancers compared to matched normal
tissues; moreover, increased p73 expression significantly corre-
lated with the presence of a p53 defect (Cai et al, 2000).
Furthermore, increased p73 expression occurred even in instances
of LOH, suggesting that the level of expression is independent of
LOH. Increased p73 expression in tumour tissue relative to
matched normal tissue, has also been observed in oesophageal
adenocarcinomas, in preliminary work by our group (BR, unpub-
lished data). The over-expression of p73 may be a partial compen-
satory mechanism for the loss of p53 function that is commonly
p73 in oesophageal carcinoma 1501
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Table 2 Hardy–Weinberg analysis of allele distribution in controls and oesophageal cancer cases 
Genotype (n)
AT/AT AT/GC GC/GC P value 
Observed Expected Observed Expected Observed Expected 
Controls* 15 14.7 65 65.5 72 71.7 *P = ns 
Oesophageal cancer cases§ 1 5.4 41 32.2 42 46.4 §P = 0.009 
*The observed genotype frequency and allele distribution in the control population did not differ significantly from that expected under
Hardy–Weinberg equilibrium (HWE). §The observed genotype frequency and allele distribution in the oesophageal cancer population was
significantly different from that expected under HWE. 
GC
AT
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Figure 1 p73 genotyping and LOH in oesophageal cancer cases. This
shows a representative sample of results of genotyping of matched normal
(N) and tumour (T) samples. Lanes 1 and 14: Molecular weight marker (MW).
Lane 2 shows an AT/AT homozygote, which was used in each experiment as
an internal control of complete Sty 1 digestion. Lane 3, squamous carcinoma
cell line OE21, showing presence of GC allele only. Lanes 4 & 5: Matched
tissues of case A100, a GC homozygote. Lanes 6 & 7: Matched tissues from
case A95 a heterozygote, demonstrating heterozygosity in N and T tissues.
Lanes 8 & 9: Case A98, showing LOH of the AT allele in the tumour tissue.
Lanes 10 & 11: Case A56, a heterozygote. Lanes 12 & 13: Case A 91,
showing LOH of the AT allele in the T tissue observed in oesophageal cancers, though obviously this is not
sufficient to prevent the development of cancer. Conflicting
reports show predominant mono-allelic (Kaghad et al, 1997; Mai
et al, 1998b; Yokomizo et al, 1999) or bi-allelic p73 expression in
various normal tissues studied. We found predominant bi-allelic
p73 expression in normal and cancerous oesophageal tissues;
mono-allelic expression of p73 was observed in only 17% of
normal tissues analysed (BR, unpublished data). Qualitative loss
of the AT allele, despite a quantitative increase in overall p73
expression, may be important in oesophageal epithelial function:
Differential  p73 function or splice variant expression, perhaps
related to this AT/GC polymorphism could potentially play a crit-
ical role in determining the development, or progression of early
oesophageal lesions. 
Recently it has been shown that p73 knockout mice develop
severe gastrointestinal inflammation, suggesting that p73 may
modulate inflammatory responses in the gastrointestinal tract
mucosa (Yang et al, 2000). The p73-deficient mice were not
observed to have an increased incidence of spontaneous tumours,
however, the majority died early, within the first 30 days of life
due to severe gastrointestinal haemorrhage (Yang et al, 2000).
Chronic gastro-oesophageal reflux is known to predispose to the
development of chronic oesophagitis with subsequent evolution of
the Barrett’s metaplasia-to-dysplasia-to-carcinoma sequence. In
this context, the findings our study suggest that the p73 AT allele
might play a role in oesophageal mucosal regulation and in
oesophageal carcinogenesis in a Caucasian population, perhaps
through modulation of the inflammatory response to chronic
gastro-oesophageal reflux. 
The current report included 25 squamous carcinomas, and
similar results were found to those in adenocarcinomas; while
chronic oesophageal inflammation is a well-recognised precursor
of oesophageal adenocarcinoma, the same does not apply for the
pathogenesis of squamous carcinoma. However chronic irritation
and inflammation of the oesophagus in response to other environ-
mental factors such as alcohol, is also thought to play a role in the
development of squamous carcinoma of the oesophagus. 
The role of this AT/GC polymorphism in modulating p73 func-
tion requires further assessment. However, as the polymorphism is
non-coding, unravelling the precise mechanisms through which it
modulates p73 function, either qualitatively or quantitatively will
be complex. Potential mechanisms include regulation of p73
expression at a transcriptional or translational level. 
Clinically, genotyping for this polymorphism may lead to better
identification of patients who are at increased risk of developing
oesophageal cancer. This could prove of particular value in the
management and surveillance of patients with Barrett’s oesoph-
agus, as intensive screening might be reserved for those with an
increased genetic risk of developing oesophageal cancer. Indeed,
given the recent observation that prolonged oesophageal reflux
may constitute a risk factor for development of oesophageal
cancer, even in the absence of Barrett’s mucosa (Lagergren et al,
1999); then it may also prove necessary in the future, to identify
patients with reflux oesophagitis, who are at risk of progression to
oesophageal cancer. 
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